Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study
Abstract Background Relugolix, an oral gonadotrophin-releasing hormone receptor antagonist, was launched in Japan in 2019. Although there have been several studies on relugolix for leiomyomas, few have focused on submucosal leiomyomas. Submucosal leiomyomas cause bleeding more frequently than leiomy...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2023-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|